### ðŸ«  Heart Failure: Evaluation of Dyspnea in Patients With Left Ventricular Assist Device

#### âœ… True Statements
1. Common complications after **left ventricular assist device (LVAD)** placement include **heart failure**, **gastrointestinal (GI) bleeding**, **driveline infections**, **arrhythmias**, **stroke**, and **hemolysis**.
2. **Gastrointestinal bleeding** after **LVAD placement** is often associated with **arteriovenous malformations** in the **small bowel**.
3. Mechanisms contributing to **LVAD-associated GI bleeding** include **reduced pulsatility**, **anticoagulation**, **impaired von Willebrand factor and platelet function**, and **endothelial dysfunction**.
4. Patients with **LVAD-associated GI bleeding** may present with **overt bleeding**, **fatigue**, or **exertional dyspnea**.
5. In patients with an LVAD and **no evidence of fluid overload**, **hemoglobin testing** is the most appropriate test to evaluate **exertional dyspnea**.
6. **Valsartan-sacubitril** interferes with **B-type natriuretic peptide (BNP)** interpretation due to **neprilysin inhibition**; instead, **N-terminal proâ€“BNP** should be used.
7. **Echocardiography** may help assess **pump function** and **pump thrombosis**, especially if **hemolysis** or **decreased pump function** is suspected.
8. Tests for **hemolysis** (e.g., **lactate dehydrogenase**, **haptoglobin**, **plasma free hemoglobin**) should be performed **only after anemia has been confirmed**.
9. The incidence of **pump-associated hemolysis** is low with **newer LVAD designs**.

#### ðŸ’¬ Extra
5. The patient described had exertional dyspnea without signs of fluid overload (e.g., no jugular venous distention, peripheral edema, or weight change), making anemia evaluation more appropriate than imaging or natriuretic peptide testing.
6. Neprilysin inhibitors reduce breakdown of BNP but do not affect N-terminal proâ€“BNP levels, making the latter a preferred diagnostic tool in such patients.
7. Echocardiography may be second-line after anemia workup if initial labs are unrevealing.
8. Hemolysis is not the first suspected cause without documented anemia and is less likely due to advanced device technology.

#### ðŸ”· Tags
#Cardiology #AmbulatoryCare #PatientOver65 #LVAD #Dyspnea #GIBleeding #Hemoglobin #BNP #Hemolysis #PumpThrombosis

#### ðŸ“™ Reference
Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. *JAMA*. 2022;328:1233-1242. PMID: 36074476 doi:10.1001/jama.2022.16197

#### ðŸ†” Question ID
CVMCQ24084

#### ðŸ•’ Last Updated
January 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Heart Failure, Advanced Refractory Heart Failure, Mechanical Circulatory Support

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. Newer **continuous-flow LVADs** provide **1-year survival** approximating that of **cardiac transplant recipients**.
2. **Five-year survival** after **LVAD implantation** is approximately **54%**.
3. Use of **LVADs as destination therapy** is increasing.
4. Indications for **LVAD placement** include **left ventricular ejection fraction (LVEF) <25%**, **New York Heart Association (NYHA) class III/IV symptoms**, **poor exercise tolerance**, and **inotrope dependency** despite **maximally tolerated therapy**.
5. **Blood pressure** in patients with **continuous-flow LVADs** must be measured by **Doppler** due to absence of palpable pulse.
6. **Anticoagulation** is part of standard therapy after **LVAD implantation** to prevent **pump thrombosis**.
7. Major **2-year complication rates** with current-generation LVADs include: **infections (58.3%)**, **arrhythmias (35.9%)**, **GI bleeding (24.5%)**, **stroke (9.9%)**, and **pump thrombosis (1.4%)**.
8. **Small-bowel arteriovenous malformations** are a common source of **GI bleeding** in **LVAD patients**.
9. The **incidence of complications** from LVADs is **decreasing** with **technological advancements**.

#### ðŸ”· Tags
#LVAD #HeartFailure #MechanicalCirculatorySupport #CardiacTransplant #DestinationTherapy #DopplerBP #GIBleeding #NYHA #Complications